ArticleJournal for immunotherapy of cancer2018
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
Article in Journal for immunotherapy of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Clinical characteristics, management and outcomes in immune checkpoint inhibitor-induced central nervous system demyelinating disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.Journal of neuro-oncology · 2022Pooled it
- Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases.BioMed research international · 2021Pooled it
- Polyradiculoneuropathies associated with immune checkpoint inhibitors: are we facing a new nosological entity?Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Longitudinally extensive transverse myelitis after pembrolizumab and lenvatinib therapy for a rare subtype of renal cell carcinoma: A case report.Oncology letters · 2025Article
- Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.Heliyon · 2024Review
- Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors.Frontiers in neuroscience · 2023Review
- Drug-related immune-mediated myelopathies.Frontiers in neurology · 2022Review
- Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series.Journal of critical care · 2021Article
- Neurotoxicities associated with immune checkpoint inhibitor therapy.Journal of neuro-oncology · 2021Article
- Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.Journal of neuro-oncology · 2021Observational
- Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature.Journal of neurology · 2021Review
- Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab.Frontiers in neurology · 2021Article
- Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review.Therapeutic advances in drug safety · 2021Article
- Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development.Clinical Medicine Insights. Oncology · 2021Review
- How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation.Hematology. American Society of Hematology. Education Program · 2020Review
- Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department.Journal of the American College of Emergency Physicians open · 2020Article
- Neurological adverse effects due to programmed death 1 (PD-1) inhibitors.Journal of neuro-oncology · 2020Article
- A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab.Journal for immunotherapy of cancer · 2020Article
- Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature.Frontiers in neurology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPD-1 and CTLA-4 inhibitors are associated with several adverse events including a spectrum of immune-related adverse effects (irAEs). Neurologic irAEs are uncommon occurrences with varied presentations. We describe two separate cases of ipilimumab associated meningoencephalomyelitis and demyelinating polyneuropathy with unusual presentations. CASE PRESENTATION: Two melanoma patients were treated with ipilimumab in the adjuvant setting. The first patient developed a meningoencephalitis following 3 doses of ipilimumab. MRI imaging of the brain confirmed leptomeningeal enhancement although cerebrospinal fluid (CSF) analyses were negative for malignant cells consistent with meningoencephalomyelitis. Although she initially improved following treatment with steroids and intravenous immunoglobulin, she subsequently relapsed. She was successfully treated with infliximab and made a complete neurological recovery. A second patient developed progressive lower extremity weakness following two doses of ipilimumab. MRI imaging of the spine confirmed diffuse nerve root enhancement consistent with acute inflammatory demyelinating polyneuropathy (AIDP). He was treated with high dose steroids with resolution of neurological symptoms. Both patients remain disease free.
conclusionsNeurological irAEs are uncommon adverse events in the context of CTLA-4 and/or PD-1 inhibitor therapy. Care must be taken to distinguish these from leptomeningeal disease. Early recognition of neurological irAEs is critical for the initiation of specific anti-inflammatory agents to prevent and potentially reverse neurological sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.